Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary

BJU Int. 2023 May;131(5):566-568. doi: 10.1111/bju.15966. Epub 2023 Jan 25.

Authors

Tobias Klatte¹, Sarah J Welsh^{2

3}, Antony C P Riddick³, José A Karam⁴, Grant D Stewart^{2

3}

Affiliations

¹ Charité-Universitätsmedizin Berlin, Berlin, Germany.
² University of Cambridge, Cambridge, UK.
³ Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁴ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 36638048
DOI: 10.1111/bju.15966

No abstract available

Keywords: cava thrombus; neoadjuvant; systemic treatment; thrombus; tyrosine kinase inhibitor.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Renal Cell* / surgery
Humans
Kidney Neoplasms* / surgery
Neoplastic Cells, Circulating* / pathology
Nephrectomy
Retrospective Studies
Thrombectomy
Tyrosine Kinase Inhibitors
Vena Cava, Inferior / pathology
Venous Thrombosis* / drug therapy
Venous Thrombosis* / surgery

Substances

Tyrosine Kinase Inhibitors